Company Analysis
Sign in

Actinium Pharmaceuticals, Inc (ATNM)

NYSE: ATNM · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Full chart Alerts Compare
Grade4.3
◀ Past 3.5● Present 3.7▶ Future 5.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$90,000+11.1%
Net income-$33.9M+11.4%
Earnings per share$-1.09+14.2%
Operating cash flow-$24.6M+25.7%
Cash$48.0M-34.2%
Debtn/a
Shareholders’ equity$7.8M-76.1%
Shares, diluted31.2M+3.7%
Return on equity-432.6%
The recordfrom its filings
Filings in 202622
Newest filingOct 16 · 4
Annual reportMar 30, 2026
Quarterly reportAug 7, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income $11.3MCash from operations -$22.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 15, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
Oct 15, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ATNM · research, not advice